Fibroblast Growth Factor Receptor 4 drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Oncology, Gastrointestinal, and Metabolic Disorders which include the indications Solid Tumor, Hepatocellular Carcinoma, Constipation, Oral Mucositis, Type 2 Diabetes, and Obesity. It also reviews key players involved in Fibroblast Growth Factor Receptor 4 targeted therapeutics development with respective active and dormant or discontinued products.

The Fibroblast Growth Factor Receptor 4 pipeline targets constitutes close to 39 molecules. Out of which, approximately 36 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, Discovery, and Unknown stages are 2, 5, 9, 16, 6, 11, 6, and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical, and Discovery comprises 1, 2, and 1 molecule.

Fibroblast Growth Factor Receptor 4 overview

Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades.

For a complete picture of Fibroblast Growth Factor Receptor 4’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.